Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

January 3, 2025 • Why the FBI believes Shamsud-Din Jabbar, the suspect behind the deadly New Orleans attack on New Year's Day, acted alone. And, how Mike Johnson's House Speaker vote could get ...

The English We Speak is your chance to catch up on the very latest English words and phrases. In under 3 minutes, we help you stay ahead of the pack by giving you 'must have' phrases that you can ...

NPR's Up First is the news you need to start your day. The three biggest stories of the day, with reporting and analysis from NPR News — in 10 minutes. Available weekdays at 6:30 a.m. ET, with ...